Trial Profile
A Pilot Trial to Assess the Effect of CNI Conversion to Efalizumab in T Regulatory Cells in Renal Transplantation
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Efalizumab (Primary) ; Sirolimus
- Indications Transplant rejection
- Focus Pharmacodynamics
- 12 Jul 2011 New trial record